Experienced in Infantile Myofibromatosis

Dr. Marvin J. Feldman

Hematology Oncology | Hematology | Oncology
227 St Paul Place, 4th Floor, 
Baltimore, MD 
Experienced in Infantile Myofibromatosis
227 St Paul Place, 4th Floor, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marvin Feldman is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Feldman is rated as an Experienced provider by MediFind in the treatment of Infantile Myofibromatosis. His top areas of expertise are Anal Cancer, Laryngeal Cancer, Familial Colorectal Cancer, and Angiosarcoma.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

227 St Paul Place, 4th Floor, Baltimore, MD 21202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: December 29, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, Carboplatin, Cisplatin, Etoposide, Temozolomide
Study Phase: Phase 2
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

4 Total Publications

Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704.
Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704.
Journal: The oncologist
Published: July 24, 2019
Similar Doctors
Distinguished in Infantile Myofibromatosis
Dr. John A. Abraham
Orthopedics | Hematology | Oncology
Distinguished in Infantile Myofibromatosis
Dr. John A. Abraham
Orthopedics | Hematology | Oncology
231 Granite Run Dr, 
Lancaster, PA 
 (56.1 miles away)
267-715-0700
Languages Spoken:
English
See accepted insurances

John Abraham is an Orthopedics specialist and a Hematologist in Lancaster, Pennsylvania. Dr. Abraham is rated as a Distinguished provider by MediFind in the treatment of Infantile Myofibromatosis. His top areas of expertise are Infantile Myofibromatosis, Congenital Generalized Fibromatosis, Desmoid Tumor, Hip Replacement, and Osteotomy.

Advanced in Infantile Myofibromatosis
Dr. Dennis A. Priebat
Hematology Oncology | Oncology
Advanced in Infantile Myofibromatosis
Dr. Dennis A. Priebat
Hematology Oncology | Oncology
110 Irving St Nw, Suite 2a38, 
Washington, DC 
 (33.0 miles away)
202-877-2505
Languages Spoken:
English
See accepted insurances

Dennis Priebat is a Hematologist Oncology specialist and an Oncologist in Washington, Washington, D.c.. Dr. Priebat is rated as a Distinguished provider by MediFind in the treatment of Infantile Myofibromatosis. His top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Rhabdomyosarcoma Embryonal.

Experienced in Infantile Myofibromatosis
Dr. Barry R. Meisenberg
Hematology Oncology | Hematology | Oncology
Experienced in Infantile Myofibromatosis
Dr. Barry R. Meisenberg
Hematology Oncology | Hematology | Oncology

Luminis Health Medical Group, LLC

2003 Medical Pkwy, Suite 301, 
Annapolis, MD 
 (21.3 miles away)
443-481-3717
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Barry Meisenberg is a Hematologist Oncology specialist and a Hematologist in Annapolis, Maryland. Dr. Meisenberg has been practicing medicine for over 44 years and is rated as an Advanced provider by MediFind in the treatment of Infantile Myofibromatosis. His top areas of expertise are Acquired Hemophilia, Hemophilia B, Cryoglobulinemia, Familial Mixed Cryoglobulinemia, and Colonoscopy. Dr. Meisenberg is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Feldman's expertise for a condition
ConditionClose
    View All 34 Advanced Conditions
    View All 111 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile